ESMO Abstracts:
CheckMate 067 Results at ESMO 2020
Abstract No : Abstract: #1105P
Indication : Melanoma
Intervention : Nivolumab
Company : Bristol-Myers Squibb
Technology : PD-1/PD-L1 inhibitor
Mixture models adequately captured the survival plateaus in CheckMate 067 and suggested a higher proportion of LTSs with NIVO and NIVO+IPI than with IPI. These methods may be used in the indirect estimation of auxiliary outcomes, such as time to subsequent treatment and impact of subsequent treatments on LTSs.
Read More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-067-NCT01844505-esmo-2020
CheckMate -577 Results at ESMO 2020
Abstract No : Abstract: #LBA9
Indication : Esophageal Cancer, Gastroesophageal junction cancer
Intervention : Nivolumab
Company : Bristol-Myers Squibb
Technology : PD-1/PD-L1 inhibitor
Adjuvant nivolumab is the first therapeutic to provide a statistically significant and clinically meaningful improvement in DFS vs placebo and a well-tolerated safety profile in patients with resected EC/GEJC, who have received neoadjuvant CRT. These results represent the first treatment advance in many years for these patients, potentially establishing adjuvant nivolumab as a new standard of care.
Read More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-577-esmo-2020
KEYNOTE-590 Results at ESMO 2020
Abstract No : Abstract #LBA8
Indication : Esophageal cancer
Intervention : Pembrolizumab
Company : Merck & Co.
Technology : PD-1/PD-L1 inhibitor
Pembro + chemo provided superior OS, PFS, and ORR vs chemo, with a manageable safety profile in pts with untreated, advanced esophageal and EGJ cancer. These data demonstrate that 1L pembro + chemo is a new standard of care in this pt population.
Read More: https://www.delveinsight.com/esmo-conference-2020/article/keynote-590-NCT03189719-esmo-2020
ASCO Abstracts:
ASCO: Results of KEYNOTE-426
Abstract No : 5001
Abstract Type : Oral Abstract Session
Indication : Renal Cell Carcinoma
Intervention : Pembrolizumab + axitinib
Company : Merck & Co.
Technology : Immune Checkpoint Inhibitor (ICI)
Pembro + axi continued to demonstrate superior and durable antitumor activity vs sunitinib in pts with first-line aRCC with a 27-mo median follow up; no new safety signals were observed.
Read More: https://www.delveinsight.com/asco-conference/article/NCT02853331